Zinc and Bone Turnover Study in Adolescent Females
Primary Purpose
Bone, Growth, Osteoporosis
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Zinc Sulfate
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Bone focused on measuring Zinc, Bone, Adolescents, Growth
Eligibility Criteria
Inclusion Criteria:
- Healthy
- Female
- Ages 9-11
- Pre-menarchal
- Caucasian or African American
Exclusion Criteria:
- Menses
- Disease known to affect bone
- Drugs known to affect bone
- Vitamin/mineral supplements
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Zinc Sulfate
Cellulose Pill
Arm Description
Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
Subject enrolled in this arm will receive a placebo.
Outcomes
Primary Outcome Measures
Serum Zinc
Serum Zinc will be measured at the Baseline and 4 week time point to determine effects of placebo vs. supplement.
Plasma IGF-1 and IGFBP-3
Plasma IGF-1 and IGFBP-3 will be measured at Baseline and 4-weeks and analyzed using ELISA to determine changes.
procollagen type 1 amino-terminal propeptide (P1NP)
Bone turnover marker procollagen type 1 amino-terminal propeptide,
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01892098
Brief Title
Zinc and Bone Turnover Study in Adolescent Females
Official Title
Supplemental Zinc and Bone Turnover in Early Pubertal Females
Study Type
Interventional
2. Study Status
Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
June 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Georgia
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to determine the effects of zinc supplementation on bone growth over four weeks. Participants will agree to attend two visits to our laboratory and at each will complete blood and urine samples, questionnaires related to diet and physical activity and will receive a bone scan at the first appointment.
Detailed Description
Significant accomplishments have been achieved with respect to our understanding of calcium and vitamin D and skeletal health, yet a body of scientific evidence has also identified understudied nutrients that have potential for reducing the burden of osteoporosis. Zinc has important roles in bone metabolism and there are indications from animal and human studies that beyond correcting skeletal and growth impairments under deficiency conditions, supplementation with zinc may have a bone health-promoting role. It has been postulated that the action of zinc on bone metabolism is partially mediated by Insulin-like growth factor one (IGF-I). Prior to undertaking a long-term bone trial, a short-term zinc supplementation trial is proposed to first determine if zinc alters intermediate markers of bone metabolism in healthy, early pubertal females (9-10.5 years of age). We hypothesize that healthy females receiving 24 mg zinc /day over 4 weeks will have elevated serum markers of bone formation and plasma growth factors compared to those receiving placebo. We further hypothesize that the differences between the zinc and placebo groups will vary by race. To test these hypotheses, we will screen early pubertal females to assure similar maturational status and conduct a 3-week, randomized, double-blind, placebo-controlled trial with a zinc supplementation (zinc sulfate; n=80) and a placebo (n=80) arm. The groups will be further divided by race (non-Hispanic White and non-Hispanic Black; n=40 per group). The specific aims are to determine if early pubertal females supplemented with zinc compared to those receiving placebo will have: 1) greater increases in markers of bone turnover favoring bone formation; 2) greater increases in plasma IGF-1 and IGFBP-3; and 3) changes in bone turnover markers, IGF-1 and IGFBP-3 that differ by race. In addition, anthropometric measures, maturity offset, sexual maturation, erythrocyte superoxide dismutase activity, ceruloplasmin, dietary intakes and physical activity will be determined. Findings from this study will provide preliminary evidence of whether supplementation with zinc is a viable nutrition strategy to improve biochemical indices of bone turnover and growth factors in young females. Moreover, the results will help determine if a long-term clinical bone trial is warranted to more definitely assess the potential for supplemental zinc to reduce the risk for osteoporosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone, Growth, Osteoporosis
Keywords
Zinc, Bone, Adolescents, Growth
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
147 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Zinc Sulfate
Arm Type
Active Comparator
Arm Description
Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
Arm Title
Cellulose Pill
Arm Type
Placebo Comparator
Arm Description
Subject enrolled in this arm will receive a placebo.
Intervention Type
Dietary Supplement
Intervention Name(s)
Zinc Sulfate
Intervention Description
9mg elemental zinc via 23mg zinc sulfate/day
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Cellulose pill given as placebo
Primary Outcome Measure Information:
Title
Serum Zinc
Description
Serum Zinc will be measured at the Baseline and 4 week time point to determine effects of placebo vs. supplement.
Time Frame
4 weeks
Title
Plasma IGF-1 and IGFBP-3
Description
Plasma IGF-1 and IGFBP-3 will be measured at Baseline and 4-weeks and analyzed using ELISA to determine changes.
Time Frame
4 weeks
Title
procollagen type 1 amino-terminal propeptide (P1NP)
Description
Bone turnover marker procollagen type 1 amino-terminal propeptide,
Time Frame
4 weeks
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
9 Years
Maximum Age & Unit of Time
11 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy
Female
Ages 9-11
Pre-menarchal
Caucasian or African American
Exclusion Criteria:
Menses
Disease known to affect bone
Drugs known to affect bone
Vitamin/mineral supplements
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard D Lewis, PhD
Organizational Affiliation
The University of Georgia
Official's Role
Principal Investigator
12. IPD Sharing Statement
Citations:
PubMed Identifier
28592518
Citation
Lobene AJ, Kindler JM, Jenkins NT, Pollock NK, Laing EM, Grider A, Lewis RD. Zinc Supplementation Does Not Alter Indicators of Insulin Secretion and Sensitivity in Black and White Female Adolescents. J Nutr. 2017 Jul;147(7):1296-1300. doi: 10.3945/jn.117.248013. Epub 2017 Jun 7.
Results Reference
derived
PubMed Identifier
26574958
Citation
Kindler JM, Pollock NK, Laing EM, Jenkins NT, Oshri A, Isales C, Hamrick M, Lewis RD. Insulin Resistance Negatively Influences the Muscle-Dependent IGF-1-Bone Mass Relationship in Premenarcheal Girls. J Clin Endocrinol Metab. 2016 Jan;101(1):199-205. doi: 10.1210/jc.2015-3451. Epub 2015 Nov 17.
Results Reference
derived
PubMed Identifier
26491117
Citation
Berger PK, Pollock NK, Laing EM, Chertin V, Bernard PJ, Grider A, Shapses SA, Ding KH, Isales CM, Lewis RD. Zinc Supplementation Increases Procollagen Type 1 Amino-Terminal Propeptide in Premenarcheal Girls: A Randomized Controlled Trial. J Nutr. 2015 Dec;145(12):2699-704. doi: 10.3945/jn.115.218792. Epub 2015 Oct 21.
Results Reference
derived
Learn more about this trial
Zinc and Bone Turnover Study in Adolescent Females
We'll reach out to this number within 24 hrs